Sorafenib improves the postoperative effect of early stage renal cell carcinoma

Taiyang Liu, Jie Li, Xiuhua Wen, Zhang Hui, Gui Qi
Published 2016 in Oncology letters

Abstract

Sorafenib was examined to determine whether it improves postoperative effects during early stage renal cell carcinoma (RCC). A total of 133 patients with early renal clear cell carcinoma (T1-2N0M0) with surgical indications were continuously selected. The patients were divided into 3 groups according to different treatments, including the surgery alone… (More)

DOI: 10.3892/ol.2016.5243

WH Shi, YH Bian, XH Song, JC Wu
Prog Mod Biomed
2011

Sorafenib improves the postoperative effect of early stage renal cell carcinoma

Abstract

Topics

4 Figures and Tables

Cited By

References

Response to Editorial Comment to Features, risk factors and clinical outcome of "very late" recurrences after surgery for localized renal carcinoma: A retrospective evaluation of a cohort with a minimum of 10 years of follow up.

Surgical Treatment of Renal Cell Carcinoma With Cavoatrial Involvement: A Systematic Review of the Literature.

Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents

Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.

Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma

Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review.

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.

Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.

Co-administration of Sorafenib with adriamycin inhibits cell proliferation in hepatocellular carcinoma cells HepG2

Slides referencing similar topics

Sorafenib improves the postoperative effect of early stage renal cell carcinoma

Abstract

Topics

4 Figures and Tables

Cited By

References

Response to Editorial Comment to Features, risk factors and clinical outcome of "very late" recurrences after surgery for localized renal carcinoma: A retrospective evaluation of a cohort with a minimum of 10 years of follow up.

Surgical Treatment of Renal Cell Carcinoma With Cavoatrial Involvement: A Systematic Review of the Literature.

Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents

Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.

Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma

Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review.

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.

Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.

Co-administration of Sorafenib with adriamycin inhibits cell proliferation in hepatocellular carcinoma cells HepG2

Similar Papers

Slides referencing similar topics